2025
Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial
Patel R, Kumskova M, Kodali H, Budnik I, Kuznetsov V, Jain A, Jha A, Thedens D, Dhanesha N, Sutariya B, Nagarkatti K, Lamb J, Kamat P, Shi Y, Avery B, Imai T, Jin X, Chauhan A, Boisserand L, Khan M, Dhandapani K, Sanganahalli B, Sansing L, Hess D, Koehler R, McCullough L, Aronowski J, Ayata C, Diniz M, Lyden P, Planas A, Chamorro A, Chauhan A, Leira E, Investigators O. Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial. Stroke 2025, 56: 965-973. PMID: 40091742, PMCID: PMC11932773, DOI: 10.1161/strokeaha.124.048748.Peer-Reviewed Original ResearchConceptsUA-treated animalsPrimary functional outcomeFunctional outcomesMiddle cerebral artery filament occlusionModified intention-to-treat populationIntention-to-treat populationUric acidHuman clinical trialsImprove functional outcomesStudy drugIntravenous salineEffects of UARelevant to patientsClinical trialsPrimary outcomeSaline controlsSecondary outcomesPreclinical trialsDay 2Survival rateDay 7Filament occlusionGroups of animalsComorbiditiesDiverse comorbiditiesGlucarpidase for Treatment of High-Dose Methotrexate Toxicity
Gupta S, Kaunfer S, Chen K, Dias J, Vijayan A, Rajasekaran A, Prosek J, Truong H, Wood A, Bassil C, Renaghan A, Shah C, Zhang J, Glezerman I, Carlos C, Kelly K, Passero C, Drappatz J, Abudayyeh A, Shin D, Sperati C, Yelvington B, Kanduri S, Neyra J, Edmonston D, Shirali A, Bansal A, Geara A, Mithani Z, Ziolkowski S, Rashidi A, Jakubowski J, Pujari A, Bond D, Dotson E, Wall S, Patton J, Barreto J, Herrmann S, Sheikh M, Baz R, Lee J, Lucchesi N, Kolman M, Rasheed M, Afzal A, Kang D, Mahesh A, Hsu R, Nicolaysen A, Tefera K, Schretlen C, Miller R, Velez J, Flannery A, Aklilu A, Anand S, Chandrasekhara S, Donley V, Patel A, Ni J, Krishnamurthy S, Ali R, Yilmam O, Wells S, Ortega J, Green-Lingren O, Leaf R, Sise M, Nayak L, LaCasce A, Leung N, Leaf D. Glucarpidase for Treatment of High-Dose Methotrexate Toxicity. Blood 2025 PMID: 39760780, DOI: 10.1182/blood.2024026211.Peer-Reviewed Original ResearchAcute kidney injuryHigh-dose methotrexate toxicityKidney recoveryPatients treated with glucarpidaseRates of acute kidney injuryDay 7Time to deathHigh-dose methotrexateCox regression modelsGlucarpidase administrationDialysis-dependentMethotrexate toxicityMethotrexate initiationKidney injuryClinical dataGlucarpidaseCancer CenterNeutropeniaEnd pointsMethotrexatePatientsHospital dischargeOutcomesTarget trial emulation frameworkDaysSystem vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans
Cortese M, Hagan T, Rouphael N, Wu S, Xie X, Kazmin D, Wimmers F, Gupta S, van der Most R, Coccia M, Aranuchalam P, Nakaya H, Wang Y, Coyle E, Horiuchi S, Wu H, Bower M, Mehta A, Gunthel C, Bosinger S, Kotliarov Y, Cheung F, Schwartzberg P, Germain R, Tsang J, Li S, Albrecht R, Ueno H, Subramaniam S, Mulligan M, Khurana S, Golding H, Pulendran B. System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans. Nature Immunology 2025, 26: 116-130. PMID: 39747435, DOI: 10.1038/s41590-024-02036-z.Peer-Reviewed Original ResearchConceptsHuman bone marrow plasma cellsResponse longevityBone marrow plasma cellsAntibody responseVaccine-induced antibody responsesAntibody response magnitudesH5N1 influenza vaccineMIF-CD74 axisInvestigate immune responsesBlood transcriptional signaturesAS03-adjuvantedInfluenza vaccineMegakaryocyte activityResponse durabilityAnalysis of predictorsPlasma cellsVaccine durabilityImmune responseDay 7Transcriptional signaturePromote survivalCell-cell interactionsAntibodiesPlateletVaccine
2024
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone
Patidar K, Tu W, Cotter T, Simonetto D, Asgharpour A, Jan M, Tang Q, Yu Y, Li Y, Taiwo M, Nagesh P, Dasarathy S, Kamath P, McClain C, Chalasani N, Szabo G, Bataller R, Mitchell M, Mehal W, Nagy L, Shah V, Gawrieh S, Sanyal A, Investigators F. Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone. Hepatology 2024, 81: 1256-1268. PMID: 39028887, PMCID: PMC11829732, DOI: 10.1097/hep.0000000000001019.Peer-Reviewed Original ResearchMultivariable competing-risk analysisCompeting-risk analysisTreatment armsKidney injuryRisk factorsWhite blood cell countMulticenter randomized clinical trialAcute kidney injuryKidney injury biomarkersBaseline risk factorsBlood cell countRandomized clinical trialsAKI developmentClinical factorsPrednisoneFollow-upHepatic encephalopathyArterial pressureClinical trialsDay 7Cell countPatientsTrialsBaselineLower survival292-OR: Coenzyme A Synthase Knockdown Alleviates Metabolic Dysfunction–Associated Steatohepatitis via Decreasing Cholesterol in Liver Lipid Droplets
SAKUMA I, GASPAR R, NASIRI A, KAHN M, GUERRA M, YIMLAMAI D, MURRAY S, PERELIS M, BARNES W, VATNER D, PETERSEN K, SAMUEL V, SHULMAN G. 292-OR: Coenzyme A Synthase Knockdown Alleviates Metabolic Dysfunction–Associated Steatohepatitis via Decreasing Cholesterol in Liver Lipid Droplets. Diabetes 2024, 73 DOI: 10.2337/db24-292-or.Peer-Reviewed Original ResearchCholine-deficient l-amino acid-defined high-fat dietAccumulation of cholesterolMRNA expressionPlasma ALTL-amino acid-defined high-fat dietProtective effectLiver lipid dropletsType 2 diabetesPotential therapeutic approachHigh-fat dietDecreased plasma ALTFibrosis markersFree cholesterol accumulationLipid dropletsLiver inflammationDay 1Macrophage markersHepatic inflammationMouse modelMarker expressionTherapeutic approachesDay 2Day 3Day 7FibrosisEffect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection
Mohammadi K, Sleeman M, Boyapati A, Bigdelou P, Geba G, Fazio S. Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection. Journal Of Lipid Research 2024, 65: 100568. PMID: 38795859, PMCID: PMC11237931, DOI: 10.1016/j.jlr.2024.100568.Peer-Reviewed Original ResearchPlasma lipid changesIL-6R blockadePlasma lipid levelsCOVID-19 pneumoniaClinical outcomesLDL-CHDL-CLipid levelsLipid changesSystemic infectionIL-6-mediated inflammationDay 7Moderately elevated triglyceridesInfluence plasma lipid levelsBaseline lipid levelsLDL-C levelsAbnormal lipid levelsAnti-inflammatory interventionsIL-6RLower LDL-CAcute systemic infectionNo significant associationPost hoc analysisInterleukin-6 receptorStudy therapyThe nature of chronic rejection after lung transplantation: a murine orthotopic lung transplant study
Heigl T, Kaes J, Aelbrecht C, Serré J, Yamada Y, Geudens V, Van Herck A, Vanstapel A, Sacreas A, Ordies S, Frick A, Gimenez B, Van Slambrouck J, Beeckmans H, Oztürk N, Orlitova M, Vaneylen A, Claes S, Schols D, Velde G, Schupp J, Kaminski N, Boesch M, Korf H, van der Merwe S, Dupont L, Vanoirbeek J, Godinas L, Van Raemdonck D, Janssens W, Gayan-Ramirez G, Ceulemans L, McDonough J, Verbeken E, Vos R, Vanaudenaerde B. The nature of chronic rejection after lung transplantation: a murine orthotopic lung transplant study. Frontiers In Immunology 2024, 15: 1369536. PMID: 38736881, PMCID: PMC11084670, DOI: 10.3389/fimmu.2024.1369536.Peer-Reviewed Original ResearchConceptsChronic lung allograft dysfunctionChronic rejectionLung transplantationSingle cell RNASingle cell RNA profilingOrthotopic left lung transplantationComplications post-transplantationLung allograft dysfunctionMouse lung transplantationLeft lung transplantationLung transplantation studiesAllograft dysfunctionPleural infiltrationPost-transplantationBronchiolitis obliteransInnate inflammationChronic complicationsPrimary onsetEndothelial destructionTransplantationDay 7Immunological perspectiveArterial responseTransplantation studiesLungA central arteriovenous fistula reduces systemic hypertension in a mouse model
Brahmandam A, Alves R, Liu H, Gonzalez L, Aoyagi Y, Ohashi Y, Langford J, Thaxton C, Taniguchi R, Zhang W, Bai H, Yatsula B, Dardik A. A central arteriovenous fistula reduces systemic hypertension in a mouse model. JVS Vascular Science 2024, 5: 100191. PMID: 38510938, PMCID: PMC10951512, DOI: 10.1016/j.jvssci.2024.100191.Peer-Reviewed Original ResearchCentral arteriovenous fistulaArteriovenous fistulaBlood pressureAng IISystemic hypertensionVenous remodelingArteriovenous fistula creationPCNA-positive cellsPostoperative day 7Systemic blood pressureSystolic blood pressureCollagen I depositionNormotensive miceRefractory hypertensionHypertensive miceC57BL6/J miceHypertensive environmentTreated patientsAngiotensin IIMouse modelDay 7HypertensionMiceFistulaAng
2023
Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
Zhang Y, Bush M, Yazdani P, Zhan J, Wen B, Bainbridge V, Wynne B, Joshi S, Lataillade M. Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants. Pharmacology Research & Perspectives 2023, 11: e01151. PMID: 37961928, PMCID: PMC10644204, DOI: 10.1002/prp2.1151.Peer-Reviewed Original ResearchConceptsConcentration-QTc analysisHealthy participantsQT intervalNovel HIV-1 maturation inhibitorsPlacebo-adjusted changeHIV-1 treatmentHIV-1 maturation inhibitorsMoxifloxacin doseSupratherapeutic dosePlasma concentrationsRelevant effectsFridericia's formulaTreatment periodCardiac repolarizationHeart rateMaturation inhibitorsCardiac conductionCardiac parametersDay 7QT studyDoseTime pointsGSK3640254ΔΔQTcFPharmacokineticsO-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY
Idalsoaga F, Díaz L, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Grawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, P N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. O-25 ASSESSMENT OF MODELS FOR PREDICTING RESPONSE TO CORTICOIDS TREATMENT IN ALCOHOL-ASSOCIATED HEPATITIS: A GLOBAL COHORT STUDY. Annals Of Hepatology 2023, 28: 101035. DOI: 10.1016/j.aohep.2023.101035.Peer-Reviewed Original ResearchCox regressionSevere AHCohort studyHigh mortalityAlcohol‐Associated HepatitisRetrospective cohort studyKaplan-Meier curvesShort-term mortalityGlobal cohort studyLille modelMultivariable analyzesCorticosteroid treatmentMELD scoreAH patientsSevere entitySerum bilirubinClinical variablesBetter prognosticationWorldwide cohortSevere diseasePatientsDay 7Predicting ResponseDay 4Corticosteroids
2022
Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses
Hagan T, Gerritsen B, Tomalin LE, Fourati S, Mulè MP, Chawla DG, Rychkov D, Henrich E, Miller HER, Diray-Arce J, Dunn P, Lee A, Levy O, Gottardo R, Sarwal M, Tsang J, Suárez-Fariñas M, Sékaly R, Kleinstein S, Pulendran B. Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses. Nature Immunology 2022, 23: 1788-1798. PMID: 36316475, PMCID: PMC9869360, DOI: 10.1038/s41590-022-01328-6.Peer-Reviewed Original ResearchConceptsAntibody responseDay 1Vaccine-induced antibodiesYellow fever vaccineHuman immune responseMechanisms of immunityB cell activationTranscriptional atlasFever vaccineDifferent vaccinesSystems vaccinologyImmune responseMost vaccinesDay 7Cell activationInnate immunityVaccineVaccinationImmunityCommon predictorsMolecular signaturesResponsePlasmablastsInterferonAntibodiesThe Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N, Howden CW. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. The American Journal Of Gastroenterology 2022, 117: 1158-1161. PMID: 35294415, DOI: 10.14309/ajg.0000000000001735.Peer-Reviewed Original ResearchHaematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
Mansoor R, Commons R, Douglas N, Abuaku B, Achan J, Adam I, Adjei G, Adjuik M, Alemayehu B, Allan R, Allen E, Anvikar A, Arinaitwe E, Ashley E, Ashurst H, Asih P, Bakyaita N, Barennes H, Barnes K, Basco L, Bassat Q, Baudin E, Bell D, Bethell D, Bjorkman A, Boulton C, Bousema T, Brasseur P, Bukirwa H, Burrow R, Carrara V, Cot M, D’Alessandro U, Das D, Das S, Davis T, Desai M, Djimde A, Dondorp A, Dorsey G, Drakeley C, Duparc S, Espié E, Etard J, Falade C, Faucher J, Filler S, Fogg C, Fukuda M, Gaye O, Genton B, Rahim A, Gilayeneh J, Gonzalez R, Grais R, Grandesso F, Greenwood B, Grivoyannis A, Hatz C, Hodel E, Humphreys G, Hwang J, Ishengoma D, Juma E, Kachur S, Kager P, Kamugisha E, Kamya M, Karema C, Kayentao K, Kazienga A, Kiechel J, Kofoed P, Koram K, Kremsner P, Lalloo D, Laman M, Lee S, Lell B, Maiga A, Mårtensson A, Mayxay M, Mbacham W, McGready R, Menan H, Ménard D, Mockenhaupt F, Moore B, Müller O, Nahum A, Ndiaye J, Newton P, Ngasala B, Nikiema F, Nji A, Noedl H, Nosten F, Ogutu B, Ojurongbe O, Osorio L, Ouédraogo J, Owusu-Agyei S, Pareek A, Penali L, Piola P, Plucinski M, Premji Z, Ramharter M, Richmond C, Rombo L, Roper C, Rosenthal P, Salman S, Same-Ekobo A, Sibley C, Sirima S, Smithuis F, Somé F, Staedke S, Starzengruber P, Strub-Wourgaft N, Sutanto I, Swarthout T, Syafruddin D, Talisuna A, Taylor W, Temu E, Thwing J, Tinto H, Tjitra E, Touré O, Tran T, Ursing J, Valea I, Valentini G, van Vugt M, von Seidlein L, Ward S, Were V, White N, Woodrow C, Yavo W, Yeka A, Zongo I, Simpson J, Guerin P, Stepniewska K, Price R. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine 2022, 20: 85. PMID: 35249546, PMCID: PMC8900374, DOI: 10.1186/s12916-022-02265-9.Peer-Reviewed Original ResearchConceptsUncomplicated P. falciparum malariaSevere anemiaDay 7Nadir hemoglobinParasite clearanceTreatment of uncomplicated P. falciparum malariaDay 3Risk factorsHaematological responseRate of parasite clearanceWorldWide Antimalarial Resistance NetworkArtemisinin-based regimensBackgroundPlasmodium falciparum malariaDelayed parasite clearanceMethodsIndividual patient dataMedian hemoglobin concentrationIndependent risk factorRisk of anemiaArtemisinin-based treatmentsDay 2 post treatmentDay of nadirModerately severe anemiaIndividual patient dataPatient dataMalarial anemia
2021
A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage
Martini RP, Siler D, Cetas J, Alkayed NJ, Allen E, Treggiari MM. A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care 2021, 36: 905-915. PMID: 34873674, DOI: 10.1007/s12028-021-01398-8.Peer-Reviewed Original ResearchConceptsSoluble epoxide hydrolaseAneurysmal subarachnoid hemorrhageSubarachnoid hemorrhageDHET ratiosEnd pointDay 7Day 10Primary study end pointSoluble epoxide hydrolase inhibitionCSF inflammatory cytokinesEET/DHET ratiosIncidence of DCIPrevention of DCITertiary end pointSecondary end pointsStudy end pointCerebral blood flowLength of stayEndothelial injury biomarkersEpoxide hydrolase inhibitionNeurovascular inflammationResultsTen patientsStudy drugAdverse eventsCytokine levelsMultinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience
Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K, Tidwell W, Guide A, Testani JM, Lewis JB, Dwyer JP. Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. Journal Of Cardiac Failure 2021, 28: 21-31. PMID: 34403831, DOI: 10.1016/j.cardfail.2021.07.016.Peer-Reviewed Original ResearchConceptsAcute heart failureDiuretic resistanceDiuretic therapyHeart failureUrine outputSerum chemistryRenal replacement therapySingle medical centerSingle-center experienceAHF cohortDiuretic classesHospital mortalityTotal cohortKidney functionSerum sodiumCarbonic anhydrase inhibitorsProspective studyReplacement therapyCase-level evidenceRetrospective analysisMedical CenterDay 7Own controlTherapyPatientsThe Role of Caspase-12 in Retinal Bystander Cell Death and Innate Immune Responses against MCMV Retinitis
Zhang X, Xu J, Marshall B, Dong Z, Smith SB, Zhang M. The Role of Caspase-12 in Retinal Bystander Cell Death and Innate Immune Responses against MCMV Retinitis. International Journal Of Molecular Sciences 2021, 22: 8135. PMID: 34360899, PMCID: PMC8348425, DOI: 10.3390/ijms22158135.Peer-Reviewed Original ResearchConceptsDay 14 p.MCMV retinitisBystander cell deathWT miceInfected eyesKO miceCaspase-12Innate immune responseTUNEL staining cellsMCMV infected cellsSimilar virus titersCell deathCytomegalovirus retinitisInjected eyeReal-time PCRVirus infectionImmune responseImmunohistochemical stainingSimilar numberInterferon αRetinitisNeural retinaDay 7Innate immunityVirus titersGrowth Rates of Infants Randomized to Continuous Positive Airway Pressure or Intubation After Extremely Preterm Birth
Salas A, Carlo W, T. B, Bell E, Das A, Van Meurs K, Poindexter B, Shankaran S, Younge N, Watterberg K, Higgins R, Network E, Jobe A, Caplan M, Laptook R, Oh W, Vohr B, Hensman A, Stephens B, Alksninis B, Andrews D, Angela K, Barnett S, Cashore B, Caskey M, Francis K, Gingras D, Gargus R, Johnson K, Lainwala S, Leach T, Leonard M, Lillie S, Mehta K, Moore J, Noel L, Ventura S, Walden R, Watson V, Walsh M, Fanaroff A, Newman N, Wilson-Costello D, Siner B, Zadell A, DiFiore J, Bhola M, Friedman H, Yalcinkaya G, Schibler K, Donovan E, Yolton K, Narendran V, Bridges K, Alexander B, Grisby C, Mersmann M, Mincey H, Hessling J, Gratton T, Goldberg R, Cotten C, Goldstein R, Ashley P, Auten K, Fisher K, Foy K, Freedman S, Gustafson K, Lohmeyer M, Malcolm W, Wallace D, Stoll B, Buchter S, Piazza A, Carlton D, Adams-Chapman I, Black L, Blackwelder A, Carter S, Dinkins E, Fritz S, Hale E, Hutchinson A, LaRossa M, Smikle G, Archer S, Lemons J, Dusick A, Wilson L, Hamer F, Cook A, Herron D, Lytle C, Minnich H, Berberich M, Blaisdell C, Gail D, Kiley J, Poole W, Gantz M, Newman J, Hastings B, Auman J, Huitema C, Pickett J, Wallace D, Zaterka-Baxter K, Stevenson D, Hintz S, Ball M, Bentley B, Bruno E, Davis A, DeAnda M, DeBattista A, Kohn J, Proud M, Pyle R, St. John N, Weiss H, Frantz I, Fiascone J, McGowan E, Furey A, MacKinnon B, Nylen E, Brussa A, Sibley C, Ambalavanan N, Collins M, Cosby S, Peralta-Carcelen M, Phillips V, Bailey K, Biasini F, Hopkins M, Johnston K, Krzywanski S, Nelson K, Patterson C, Rector R, Rodriguez L, Soong A, Whitley S, York S, Finer N, Rasmussen M, Wozniak P, Vaucher Y, Rich W, Arnell K, Barbieri-Welge R, Ben-Tall A, Bridge R, Demetrio C, Fuller M, Ito E, Lukasik M, Pontillo D, Posin D, Runyan C, Wilkes J, Zlotnik P, Widness J, Klein J, Colaizy T, Johnson K, Acarregui M, Eastman D, Duara S, Bauer C, Everett-Thomas R, Calejo M, Diaz A, Eguaras S, Garcia A, Hamlin-Smith K, Berkowits M, Hiriart-Fajardo S, Mathews E, Pierre H, Riguard A, Stroerger A, Ohls R, Fuller J, Rohr J, Lacy C, Lowe J, Montman R, Laroia N, Phelps D, Myers G, Markowitz G, Reubens L, Hust D, Augostino L, Johnson J, Burnell E, Gelbard H, Jensen R, Kushner E, Merzbach J, Mink J, Torres C, Wang D, Yost K, Sánchez P, Rosenfeld C, Salhab W, Heyne R, Adams S, Allen J, Grau L, Guzman A, Hensley G, Heyne E, Lepps M, Madden L, Martin M, Miller N, Morgan J, Solis A, Torres L, Boatman C, Vasil D, Wilder K, Kennedy K, Tyson J, Alaniz N, Evans P, Harris B, Green C, Jiminez M, Lis A, Martin S, McDavid G, Morris B, Poundstone M, Reddoch S, Siddiki S, Tate P, Whitely L, Wright S, Yoder B, Faix R, Baker S, Bird K, Burnett J, Cole L, Osborne K, Spencer C, Steffens M, Weaver-Lewis K, Zanetti K, O'Shea T, Dillard R, Washburn L, Peters N, Jackson B, Chiu K, Allred D, Goldstein D, Halfond R, Peterson C, Waldrep E, Welch C, Morris M, Hounshell G, Pappas A, Sood B, Bara R, Billian E, Goldston L, Johnson M, Ehrenkranz R, Bhandari V, Jacobs H, Cervone P, Gettner P, Konstantino M, Poulsen J, Taft J, Butler C, Close N, Gilliam W, Greisman S, Romano E, Williams J. Growth Rates of Infants Randomized to Continuous Positive Airway Pressure or Intubation After Extremely Preterm Birth. The Journal Of Pediatrics 2021, 237: 148-153.e3. PMID: 34157349, PMCID: PMC8478787, DOI: 10.1016/j.jpeds.2021.06.026.Peer-Reviewed Original ResearchConceptsContinuous positive airway pressurePositive airway pressureEarly continuous positive airway pressureWeeks of PMAWeeks postmenstrual agePostmenstrual ageEPT infantsAirway pressureEarly intubationNutritional intakeTreatment groupsDay 28Day 21Day 7Surfactant Positive Airway PressureTotal nutritional intakeMedian gestational ageMean birth weightBayley-III cognitive scoresPulse Oximetry TrialSurfactant administrationBaseline characteristicsPreterm infantsPreterm birthGestational ageUse of peritoneal dialysis for acute kidney injury during the COVID-19 pandemic in New York City: a multicenter observational study
Chen W, Caplin N, Shamy O, Sharma S, Sourial M, Ross M, Sourial M, Prudhvi K, Golestaneh L, Srivatana V, Dalsan R, Shimonov D, Sanchez-Russo L, Atallah S, Uribarri J, Consortium N. Use of peritoneal dialysis for acute kidney injury during the COVID-19 pandemic in New York City: a multicenter observational study. Kidney International 2021, 100: 2-5. PMID: 33930411, PMCID: PMC8079266, DOI: 10.1016/j.kint.2021.04.017.Peer-Reviewed Original ResearchConceptsAcute kidney injuryKidney replacement therapyPeritoneal dialysisReplacement therapyKidney injuryMechanical ventilationUsefulness of peritoneal dialysisDay 3Day 7Observational studyMedian follow-upAcute peritoneal dialysisMulticenter observational studyPredictors of mortalitySeverity of diseaseSerum bicarbonateAcute PDRenal recoveryPatient comorbiditiesLaboratory valuesMale sexFollow-upPatient outcomesCoronavirus disease 2019PatientsFever, pancytopenia, and elevated D-dimer in a 95‐year‐old woman with ehrlichiosis: a case report
Radcliffe C, Tsay C, Glerum K, Liao J, Goshua G, Kerins G. Fever, pancytopenia, and elevated D-dimer in a 95‐year‐old woman with ehrlichiosis: a case report. BMC Geriatrics 2021, 21: 178. PMID: 33711942, PMCID: PMC7953191, DOI: 10.1186/s12877-021-02129-6.Peer-Reviewed Original ResearchConceptsD-dimerPulmonary emboliSevere coronavirus disease 2019Hospital day 7Computed tomography angiogramSignificant clinical findingsPeripheral blood smearCoronavirus disease 2019Concurrent ehrlichiosisDoxycycline monotherapyHospital stayHigh feverSymptomatic improvementTomography angiogramCase presentationWeClinical findingsLarge academic institutionCase reportArteriovenous malformationsAppropriate treatmentDifferential diagnosisUnexpected presentationDisease 2019Hematological malignanciesDay 7
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply